# Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

> **NCT00301990** · PHASE2 · UNKNOWN · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 65 (estimated)

## Conditions studied

- Kidney Cancer

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** bevacizumab

## Key facts

- **NCT ID:** NCT00301990
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-09
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2014-01-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00301990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00301990, "Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00301990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*